- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Potentially Undervalued Companies
Hong Kong Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Jul 01, 2022
Companies with a Value score of at least 3, ordered by Value score
70 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1681Consun Pharmaceutical Group | HK$4.18 | 1.0% | -17.2% | HK$3.3b | HK$9.00 | PE4.7x | E10.3% | 6.8% | ||
| 3933United Laboratories International Holdings | HK$4.65 | -2.5% | -24.0% | HK$8.4b | HK$5.54 | PE7.3x | E7.4% | 4.0% | ||
| 2877China Shineway Pharmaceutical Group | HK$6.71 | 4.4% | -18.6% | HK$5.1b | HK$7.93 | PE7.8x | E10.3% | 6.8% | ||
| 3933United Laboratories International Holdings | HK$4.65 | -2.5% | -24.0% | HK$8.4b | HK$5.54 | PE7.3x | E7.4% | 4.0% | ||
| 1177Sino Biopharmaceutical | HK$4.97 | 5.3% | -33.5% | HK$92.8b | HK$7.77 | PE5.4x | E-38.4% | 1.5% | ||
| 6600SciClone Pharmaceuticals (Holdings) | HK$8.70 | 6.1% | n/a | HK$5.9b | HK$11.86 | PE5.4x | E-8.5% | 3.8% | ||
| 874Guangzhou Baiyunshan Pharmaceutical Holdings | HK$23.00 | 1.1% | -5.0% | HK$56.0b | HK$23.32 | PE8.2x | E0.8% | 3.5% | ||
| 1177Sino Biopharmaceutical | HK$4.97 | 5.3% | -33.5% | HK$92.8b | HK$7.77 | PE5.4x | E-38.4% | 1.5% | ||
| 1801Innovent Biologics | HK$34.90 | -3.5% | -60.2% | HK$51.2b | HK$48.79 | PS10.2x | E58.8% | n/a | ||
| 15303SBio | HK$6.24 | -6.6% | -33.9% | HK$15.2b | HK$8.34 | PE7.9x | E6.9% | 3.2% | ||
| 6185CanSino Biologics | HK$80.35 | -4.1% | -78.7% | HK$36.8b | HK$181.63 | PE8.3x | E3.9% | 1.2% | ||
| 1177Sino Biopharmaceutical | HK$4.97 | 5.3% | -33.5% | HK$92.8b | HK$7.77 | PE5.4x | E-38.4% | 1.5% | ||
| 2696Shanghai Henlius Biotech | HK$17.66 | 0.9% | -53.8% | HK$9.6b | HK$26.46 | PS4.9x | E82.2% | n/a | ||
| 2186Luye Pharma Group | HK$2.58 | -3.7% | -50.5% | HK$9.2b | HK$2.74 | PS1.5x | E51.8% | 0% | ||
| 2186Luye Pharma Group | HK$2.58 | -3.7% | -50.5% | HK$9.2b | HK$2.74 | PS1.5x | E51.8% | 0% | ||
| 6185CanSino Biologics | HK$80.35 | -4.1% | -78.7% | HK$36.8b | HK$181.63 | PE8.3x | E3.9% | 1.2% | ||
| 1801Innovent Biologics | HK$34.90 | -3.5% | -60.2% | HK$51.2b | HK$48.79 | PS10.2x | E58.8% | n/a | ||
| 6600SciClone Pharmaceuticals (Holdings) | HK$8.70 | 6.1% | -41.6% | HK$5.9b | HK$11.86 | PE5.4x | E-8.5% | 3.8% | ||
| 15303SBio | HK$6.24 | -6.6% | -33.9% | HK$15.2b | HK$8.34 | PE7.9x | E6.9% | 3.2% | ||
| 1801Innovent Biologics | HK$34.90 | -3.5% | -60.2% | HK$51.2b | HK$48.79 | PS10.2x | E58.8% | n/a | ||
| 6185CanSino Biologics | HK$80.35 | -4.1% | -78.7% | HK$36.8b | HK$181.63 | PE8.3x | E3.9% | 1.2% | ||
| 15303SBio | HK$6.24 | -6.6% | -33.9% | HK$15.2b | HK$8.34 | PE7.9x | E6.9% | 3.2% | ||
| 2186Luye Pharma Group | HK$2.58 | -3.7% | -50.5% | HK$9.2b | HK$2.74 | PS1.5x | E51.8% | 0% | ||
| 867China Medical System Holdings | HK$12.24 | -1.9% | -38.7% | HK$30.0b | HK$16.89 | PE8.5x | E8.0% | 4.7% |